Bloomage Biotechnology Corporation Limited Class A
SSSE:68836335.21
CNY
+1.00
(+2.92%)
Bloomage Biotechnology Corporation Limited Class A
SSE:688363
(Shanghai Stock Exchange)
Recent
price
35.21
P/E
ratio
54.47
div
yld
0.03%
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Bloomage BioTechnology Corporation Limited specializes in the research, development, production, and sale of hyaluronic acid (HA) and related bioactive substances. The company's main products include pharmaceutical grade sodium hyaluronate used as an active pharmaceutical ingredient (API) or excipient in ophthalmic preparations, intra-articular injections, anti-adhesive formulations, and topical wound healing and soft tissue fillers under the Hyature brand. It also offers cosmetic grade sodium hyaluronate solutions for moisturizing, repairing, anti-aging, and brightening applications under multiple brands including Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. Additionally, Bloomage produces a broad range of over 200 specifications of hyaluronic acid products for pharmaceutical, cosmetic, and food-grade applications, along with functional sugars, proteins, polypeptides, amino acids, nucleotides, natural active compounds, and other bioactive substances. Its product portfolio extends to bioactive ingredients supporting anti-aging, whitening, skin repair, humectants, sunscreen agents, anti-inflammatory, anti-pollution, protective and film-forming agents, marketed globally for medicine, medical devices, cosmetics, and nutrition sectors. Bloomage is headquartered in Shandong, China, and was founded in 2000. It operates globally with expanding international sales and partnerships across multiple continents. The company’s innovation is anchored in advanced microbial fermentation, enzymatic degradation, and cross-linking technologies, positioning it as a world leader in HA production. Recent strategic developments include the establishment of significant strategic alliances with 15 research institutions and 5 major universities to accelerate R&D; the launch of three new groundbreaking products in 2023; and an ongoing global expansion plan targeting North America and Europe, aiming for a 15% compound annual growth rate in international sales by 2026. In 2024, Bloomage allocated RMB 200 million for R&D, underscoring its commitment to innovation, including the launch of a new biocompatible polymer enhancing skin rejuvenation treatment efficacy. The company also achieved FDA GMP audit certification with zero deficiencies, reinforcing its global manufacturing standards and trust. Recent major operational changes included the growth and scaling of its nutritional science division, marking the first single-quarter profit in Q3 2025, with a focus on synthetic biology materials such as PDRN and PQQ as new growth drivers. Bloomage also formed a strategic partnership with Xcell Therapeutics in 2025 to advance cell culture media technologies. Despite some short-term earnings pressure, the company continues to project strong EPS growth through 2027. Subsidiaries include Bloomage Biotechnology (Tianjin) Co., Ltd., which focuses on fermentation, crosslinking, and traditional Chinese medicine applications. Bloomage maintains certifications such as HALAL, ECOCERT, COSMOS, Vegan, and NaTrue, supporting its position as a strategic ingredient supplier to leading global cosmetics companies. Overall, Bloomage BioTechnology Corporation Limited integrates cutting-edge biotechnology and synthetic biology to supply high-quality hyaluronic acid materials and bioactive compounds internationally, maintaining a leadership role in pharmaceutical, cosmetic, medical aesthetic, and nutritional markets while actively pursuing innovation-led growth and global market expansion.